FiercePharma

RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 18, 2013) - GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has ...
FiercePharma

RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment ...
PharmaTimes

GSK’s Relvar Ellipta hits the mark in COPD trial

A "ground-breaking" UK study has shown that GlaxoSmithKline's Relvar Ellipta is better than the standard of care in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) ...
pharmaphorum

GSK’s Relvar Ellipta comes out on top in real world study

GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist firm ...
PharmaTimes

GSK’s Relvar Ellipta shows benefit for COPD patients

Further results from the UK Salford Lung Study have been unveiled showing that GlaxoSmithKline's Relvar Ellipta is better than the standard of care in reducing exacerbations in patients with chronic ...
The Financial

Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients with COPD

The FINANCIAL — GlaxoSmithKline plc on December 2 announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar Ellipta (fluticasone furoate / vilanterol 100/25 mcg) ...
Insider Monkey

Relvar Ellipta: GlaxoSmithKline and Theravance’s Drug for Respiratory Diseases

Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the ...
The Motley Fool

Glaxo and Theravance Get European Marketing Approval for Relvar Ellipta

The drug is used to treat asthma and COPD. Relvar Ellipta is delivered once per day using Ellipta, a dry powder inhaler. The drug is used to treat both asthma and chronic obstructive pulmonary disease ...
Medindia

GSK's Relvar Approved by European Authorities

British pharmaceutical giant GlaxoSmithKline revealed that European authorities have approved its new inhaled drug Relvar for treating patients with asthma and chronic obstructive pulmonary disease ...
Yahoo Finance

RELVAR(R) ELLIPTA(R) Receives European Marketing Authorisation for the Treatment of Asthma and COPD

COPD: the symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) with a FEV 1 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular ...
Yahoo Finance

RELVAR(TM) ELLIPTA(TM) Gains Approval in Japan for the Treatment of Asthma

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 20, 2013) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese ...